Among these glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for glycaemic control in type 2 diabetes mellitus (T2DM) and for weight loss [2], offer a novel mechanism to modify neurotoxicity in individuals at-risk for AD. This evidence concerns the gene GLP1R and Alzheimer disease.